Enterococcus aviu-1 and application thereof
Through the application of Enterococcus avium Eaviu-1, the treatment problems of chemotherapy-related diarrhea were solved, safe and efficient regulation of intestinal flora and inflammation were achieved, and the treatment effect similar to loperamide drugs was demonstrated. .
Patent Information
- Application Number
- CN202410604944.3
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Priority Date
- 2023-05-16
- Filing Date
- 2024-05-15
- Publication Date
- 2024-11-22
AI Technical Summary
There is a lack of effective treatment of chemotherapy-related diarrhea in the prior art, especially safe and side-effect-free solutions.
Enterococcus avium Eaviu-1 and its derivatives are used to treat chemotherapy-related diarrhea. The strain is able to regulate the intestinal flora, alleviate the inflammatory response, and exhibit similar effects to loperamide drugs in chemotherapy-induced diarrhea.
Enterococcus aurora Eaviu-1 significantly improves chemotherapy-related diarrhea, has high safety and better antioxidant ability than Lactobacillus rhamnosus, inhibits the growth of Pseudomonas aeruginosa and Clostridium difficile, reduces intestinal inflammation, and does not inhibit the stomach. Side effects of intestinal peristalsis, suitable for long-term use.
Smart Images

Figure CN118995464A_ABST
Abstract
Description
Technical Field
[0001] The invention belongs to the field of microbial drugs and relates to an avian enterococcus Eaviu-1 and an application thereof, and specifically relates to an avian enterococcus Eaviu-1 and an application thereof in preventing or treating chemotherapy-related diarrhea. Background Art
[0002] Existing data show that the intestine is the largest micro-ecological system in the human body, with a total of about 10 14 There are more than 1,000 to 2,000 species of microorganisms weighing about 1 to 2 kilograms. The total number of genes encoded by these intestinal microorganisms exceeds 3.3 million, which is about 100 times the total number of human coding genes. Therefore, intestinal microorganisms are considered to be the second genome of the human body. Together with the human genome, the intestinal microbial genome affects human health in different ways through interactions with environmental factors.
[0003] Intestinal microorganisms are mainly bacteria, but also include fungi, viruses and bacteriophages, which maintain a dynamic balance in the human intestine. Such a large intestinal microbial community has become an important acquired "organ" that is inseparable from the human body through long-term co-evolution with the host. The functions of the intestinal microorganism "organ" are diverse, including material metabolism, biological barriers, immune regulation and host defense. Intestinal microorganisms not only help the human body absorb nutrients from food, but also synthesize amino acids, organic acids, vitamins, antibiotics, etc. for human use, and can metabolize the toxins produced to reduce toxicity to the human body. Different eating habits and lifestyles have a great impact on the types of intestinal microorganisms in the human body. For example, a high-fat diet can lead to a reduction or even disappearance of beneficial bifidobacteria. Therefore, there is a mutually beneficial symbiotic relationship between intestinal microorganisms and the human body, which plays an important role in maintaining human health.
[0004] Intestinal microorganisms can be divided into three categories based on their functions: symbiotic, probiotic and pathogenic microorganisms. Based on the understanding of their functions, people have developed a variety of probiotic products. Traditional probiotic products are mostly probiotic microorganisms, such as Bifidobacterium, Lactobacillus, Lactobacillus, etc., which can regulate the microecological environment of intestinal flora and produce short-chain fatty acids and other metabolites that are beneficial to the host, thereby exerting a probiotic function.
[0005] Second-generation probiotics, also known as live biological drugs, are microorganisms that produce health benefits to the host when ingested in sufficient quantities. They are used to prevent and treat human diseases and have the advantages of high safety and wide applicability. Compared with traditional probiotics, they have better resistance to digestive juices such as gastric acid, bile, and pancreatic juice, and can survive and reproduce better in the intestines, thereby playing a better prebiotic role and promoting intestinal health. At the same time, second-generation probiotics can also more accurately locate corresponding intestinal problems and symptoms, achieve more precise treatment effects, and play an important role in anti-infection, anti-tumor, and treatment of metabolic diseases and immune-related diseases.
[0006] The second generation of probiotics is no longer limited to the traditional probiotics. According to research, some "pathogenic bacteria" have been proven to have unique therapeutic effects in certain disease areas. For example, Bacteroides fragilis has entered clinical trials to verify its effectiveness in treating irritable bowel syndrome, inflammatory bowel disease and anti-tumor; Enterococcus faecalis, Prevotella, Escherichia coli, Salmonella, etc. also show therapeutic potential in the fields of anti-tumor and atopic dermatitis.
[0007] Enterococcus avium is a common bacterium that lives in the intestines of humans and other animals. It is more common in the feces of birds and chickens. It is not a conventional probiotic. Some of them contain virulence genes that can cause infection. In the medical field, there are no reports of using Enterococcus avium in disease treatment. Summary of the invention
[0008] The present invention is based on the study of avian enterococci and provides an avian enterococci capable of treating chemotherapy-related diarrhea and its use in medicine. The avian enterococci of the present invention has good safety and can treat chemotherapy-related diarrhea from multiple aspects of anti-oxidation, inhibition of pathogenic bacteria and pro-inflammatory factors, and repair of intestinal barriers.
[0009] In order to solve the problems existing in the prior art, the first aspect of the present invention provides a biomaterial, wherein the biomaterial is selected from the following M1, M2, M3 and M4;
[0010] M1: Enterococcus avium with a deposit number of CCTCC NO: M2023350 or a lysate thereof;
[0011] M2: a progeny strain of Enterococcus avium with a deposit number of CCTCC NO: M2023350 or a lysate thereof;
[0012] M3: a cloned strain of Enterococcus avium with a deposit number of CCTCC NO: M2023350 or a lysate thereof;
[0013] M4: pure culture of Enterococcus avium with a deposit number of CCTCC NO: M2023350 or a lysate thereof.
[0014] A second aspect of the present invention provides a method for culturing avian enterococci, the method comprising: inoculating avian enterococci with a deposit number of CCTCC NO: M2023350, a progeny strain of the avian enterococci with a deposit number of CCTCC NO: M2023350, a cloned strain of the avian enterococci with a deposit number of CCTCC NO: M2023350, or a pure culture of the avian enterococci with a deposit number of CCTCC NO: M2023350 into a culture medium, performing proliferation culture, and obtaining proliferated avian enterococci.
[0015] The third aspect of the present invention provides a composition, wherein the composition uses the biomaterial described in the first aspect of the present invention as an active material.
[0016] In some embodiments, the composition further contains an auxiliary material.
[0017] In some embodiments, the auxiliary material is selected from any one of the following materials:
[0018] Bacterial culture medium;
[0019] Lyoprotectants;
[0020] Pharmaceutically acceptable carriers or excipients;
[0021] Acceptable materials in health products;
[0022] acceptable materials in cosmetics;
[0023] Materials acceptable in food.
[0024] The fourth aspect of the present invention provides the use of the biomaterial described in the first aspect of the present invention or the composition described in the third aspect of the present invention in preparing a product for use alone, in combination with other microbial preparations and / or drugs, or as a component of a mixture composed of other microbial preparations and / or drugs to improve the health of a subject;
[0025] The improved health condition of the subject is selected from:
[0026] Treat, prevent and / or relieve chemotherapy-induced diarrhea;
[0027] Inhibiting the proliferation of Pseudomonas aeruginosa and / or Clostridium difficile in the body cavity of the subject;
[0028] Treat, prevent and / or slow down tissue damage, disease or sub-health condition caused by Pseudomonas aeruginosa and / or Clostridium difficile;
[0029] Treat, prevent and / or alleviate tissue damage, disease or sub-health condition caused by TNF-α and / or IL-6;
[0030] Improve the antioxidant capacity in the intestines of subjects.
[0031] In some embodiments, the product is a pharmaceutical product.
[0032] In some embodiments, the product is a health product.
[0033] In some embodiments, the product is a food product.
[0034] In some embodiments, the product is a cosmetic.
[0035] In some embodiments, the subject is selected from a human and a mouse.
[0036] In some embodiments, the chemotherapy drug is selected from fluorouracil chemotherapy drugs, taxane chemotherapy drugs, platinum chemotherapy drugs, topoisomerase I inhibitors, and tyrosine kinase inhibitors.
[0037] In some embodiments, the chemotherapy drug is selected from one or more of doxorubicin, epirubicin, dactinomycin D, doxorubicin, daunorubicin, paclitaxel, docetaxel, albumin-paclitaxel, cisplatin, carboplatin, nedaplatin, oxaliplatin, lobaplatin, cyclophosphamide, nitrogen mustard, carmustine, camptothecin, hydroxycamptothecin, topotecan, irinotecan, capecitabine, gemcitabine, methotrexate, fluorouracil, pemetrexed, and cytarabine.
[0038] Enterococcus avium has the following characteristics:
[0039] 1) No hemolysis;
[0040] 2) Resistant to gastric juice (pH 3.0);
[0041] 3) Has antioxidant capacity;
[0042] 4) It can inhibit the expression of pro-inflammatory factors TNF-α and IL-6.
[0043] Beneficial effects of the present invention:
[0044] 1. The avian enterococcus Eaviu-1 of the present invention has no virulence factors, is non-hemolytic, and has good safety;
[0045] 2. It has antioxidant capacity, and its effect is better than that of Lactobacillus rhamnosus GG;
[0046] 3. It has an inhibitory effect on Pseudomonas aeruginosa and Clostridium difficile, can regulate intestinal flora and inhibit the growth of pathogenic bacteria;
[0047] 4. Inhibit the expression of pro-inflammatory factors and reduce intestinal inflammatory response, with an effect comparable to that of dexamethasone;
[0048] 5. The avian Enterococcus Eaviu-1 of the present invention achieves an effect comparable to that of the chemical drug loperamide in terms of diarrhea indicators, and does not have the side effect of inhibiting gastrointestinal motility, thus being able to meet the needs of tumor patients for long-term use. BRIEF DESCRIPTION OF THE DRAWINGS
[0049] Figure 1 This is a front view photo of the colony morphology of Enterococcus avium Eaviu-1 of the present invention.
[0050] Figure 2 The results of in vitro antioxidant test of Enterococcus avium Eaviu-1 are shown.
[0051] Figure 3 The results of the antibacterial test of Enterococcus avium Eaviu-1 against pathogenic bacteria are shown.
[0052] Figure 4 The results of the in vitro cell inflammation inhibition test of Enterococcus avium Eaviu-1 are shown, A is the result of the effect on IL-6 expression, and B is the result of the effect on TNF-α expression.
[0053] Figure 5 The figure shows the therapeutic effect of each experimental group on mice with diarrhea caused by 5-fluorouracil. A is the diarrhea score curve of each group from day 1 to day 9; B is the total diarrhea score of each group. DETAILED DESCRIPTION
[0054] In order to make the objectives, technical solutions and advantages of the present invention more clear, the embodiments of the present invention will be further described in detail below with reference to the accompanying drawings.
[0055] Unless otherwise specified, the terms used herein have the common meanings in the biomedical field.
[0056] The specific temperature parameters in the present invention, unless otherwise specified, should be understood as constant temperature treatment, and are allowed to fluctuate within a certain temperature range, such as within the range of ±5°C, ±4°C, ±3°C, ±2°C, and ±1°C.
[0057] Diarrhea refers to a clinical symptom in which the frequency of bowel movements significantly exceeds the usual habit (>3 times / d), the feces are thin, the water content is increased (>85%), and the stool may be accompanied by mucus, pus, blood, or undigested food. In the present invention, its meaning covers antibiotic-related diarrhea, chemotherapy-related diarrhea, functional diarrhea, infectious diarrhea, etc.
[0058] Chemotherapy refers to the use of drugs to kill tumor cells to achieve treatment goals. It is the main means of treating tumors besides surgery and radiotherapy.
[0059] Chemotherapy-related diarrhea refers to diarrhea caused by gastrointestinal toxicity of chemotherapy drugs, including but not limited to non-targeted small molecule drugs, targeted small molecule drugs, biological macromolecule drugs, nucleic acid drugs and cell therapy drugs. Examples of these drugs include, but are not limited to, antibiotic chemotherapy drugs, such as doxorubicin, epirubicin, dactinomycin D, doxorubicin, daunorubicin and their derivatives, taxane chemotherapy drugs, such as paclitaxel, docetaxel, albumin-paclitaxel and their derivatives, etc.; platinum chemotherapy drugs, such as cisplatin, carboplatin, nedaplatin, oxaliplatin, lobaplatin and their derivatives, etc.; alkylating agent chemotherapy drugs, such as cyclophosphamide, nitrogen mustard, carmustine and their derivatives, etc.; camptothecin chemotherapy drugs, such as camptothecin, hydroxycamptothecin, topotecan, irinotecan and their derivatives, etc.; antimetabolite chemotherapy drugs, such as capecitabine, gemcitabine, methotrexate, fluorouracil, pemetrexed, cytarabine and their derivatives, etc.; targeted drugs, such as apatinib, axitinib, cabozantinib, sorafenib, sunitinib, etc.; anti-PD-1PD- / L1 antibodies, such as nivolumab and pembrolizumab.
[0060] Several or more refers to two or more types that are integers, such as two, three, four, five, six, seven...etc.
[0061] The Enterococcus avium of the present invention may be a live bacterium, or an inactivated bacterium, or a pure culture, lysate, culture fluid (such as supernatant) of the bacterium, or a component extracted from the culture.
[0062] In some embodiments, Enterococcus avium is a live bacterium, an inactivated bacterium, or a combination thereof (i.e., a combination of live bacterium and inactivated bacterium). The inactivated bacterium may be an inactivated bacterium with a complete morphological structure, an inactivated bacterium with an incomplete morphological structure, or a combination thereof.
[0063] The Enterococcus avium of the present invention includes the strain Enterococcus avium Eaviu-1 with a deposit number of CCTCC NO: M2023350, and its progeny strains (offspring) or strains cultured (cloned) from the original strain. The progeny strains and subcloned strains have similar activities to Eaviu-1.
[0064] The present invention provides a pharmaceutical composition, which contains a therapeutically or prophylactically effective amount of Enterococcus avium Eaviu-1 and a pharmaceutically acceptable carrier and / or excipient. The pharmaceutical composition is used for the treatment and prevention of diarrhea. Further, the pharmaceutical composition is used for the treatment and prevention of chemotherapy-related diarrhea.
[0065] The therapeutically effective amount or prophylactically effective amount is an amount that can achieve the desired therapeutic or prophylactic result clinically. In some embodiments, the therapeutically effective amount does not induce or cause undesirable side effects. In some embodiments, the therapeutically effective amount induces or causes side effects, but only causes side effects that are acceptable to the treating clinician in view of the patient's condition. In some embodiments, a single dose or a single effective amount contains 10 2 ~10 15 CFU, 10 3 ~10 14 CFU, 10 4 ~10 13 CFU, 10 5 ~10 12 CFU, 10 6 ~10 12 CFU, 10 7 ~10 11 CFU, 10 8 ~10 11 CFU, 10 9 ~10 11 CFU of Enterococcus avium.
[0066] A pharmaceutically acceptable carrier refers to a pharmaceutical carrier that does not cause significant stimulation to a subject and does not eliminate the biological activity and characteristics of the probiotics administered. A pharmaceutically acceptable carrier can enhance or stabilize the composition, or can be used to promote the preparation of the composition. A pharmaceutically acceptable carrier may include solvents, dispersion media, coatings, surfactants, antioxidants, isotonic agents, absorption delay agents, salts, drug stabilizers, binding agents, excipients, disintegrants, lubricants, sweeteners, flavoring agents, dyes, etc. and combinations thereof, as known to those skilled in the art (see, for example, Remington's Pharmaceutical Sciences, the 18th edition Mack Printing Company, 1990, pages 1289-1329). Unless conventional carriers are incompatible with active ingredients, it is considered to be used in therapeutic or pharmaceutical compositions. The carrier may be selected to minimize adverse side effects of the subject and / or minimize the inactivation of the active ingredient.
[0067] Excipients refer to substances added to pharmaceutical compositions to give the drug a certain shape or concentration, such as sterile water, physiological saline, polyalkylene glycols (such as polyethylene glycol), vegetable oils or hydrogenated naphthalene, calcium bicarbonate, calcium phosphate, various sugars, various types of starch, cellulose derivatives, gelatin, etc.
[0068] The pharmaceutical composition of the present invention may further contain a second beneficial active ingredient, such as another probiotic, prebiotic or drug with antidiarrhea function, and the prebiotic helps regulate the intestinal environment by promoting the growth of probiotics in the intestine, thereby indirectly playing an antidiarrhea effect. Examples of the second beneficial active ingredient include, but are not limited to, Bacillus licheniformis, Bifidobacterium, Clostridium butyricum, oligofructose, galacto-oligosaccharide, isomaltooligosaccharide, oligoxylose, oligomannose, inulin, stachyose, soybean oligosaccharide, beta-glucan, oligolactose, etc.
[0069] In some embodiments, the pharmaceutical composition is in the form of tablets, capsules, granules, solutions, suspensions, powders, etc.
[0070] The technical solutions in the embodiments of the present invention are described clearly and completely below. Obviously, the described embodiments are only part of the embodiments of the present invention, not all of them. Based on the embodiments of the present invention, all other embodiments obtained by those skilled in the art without creative work should fall within the scope of protection of the present invention.
[0071] The culture medium preparation method used in the following examples is as follows:
[0072] Preparation of YCFA medium: weigh 10.0 g of casein peptone, 2.5 g of yeast extract, 0.45 mL of MgSO4·7H2O (10% mother liquor), 0.45 mL of CaCl2 (10% mother liquor), 10 mL of TE141, 0.45 g of K2HPO4, 0.45 g of KH2PO4, 0.90 g of NaCl, and 3.2 mL of VFA-mix, dissolve in 1 L of distilled water, deoxygenate with N2 replacement and package, sterilize at 121°C for 30 min, store in a cool and dry place for later use.
[0073] Preparation of TE141: Weigh 1.50 g of nitrilotriacetic acid and add it to 200 mL of pure water, add an appropriate amount of NaOH until the solution becomes clear, then add 800 mL of water, adjust the pH value to 5.5 with 50% HCl, then weigh 3.00 g of MgSO4·7H2O, 0.50 g of MnSO4·H2O, 1.00 g of NaCl, 0.10 g of FeSO4·7H2O, 0.18 g of CoSO4·7H2O, 0.10 g of CaCl2·2H2O, 0.18 g of ZnSO4·7H2O, 0.006 g of CuSO4·5H2O, 0.02 g of KAl(SO4)2·12H2O, 0.01 g of H3BO3, 0.01 g of Na2MoO4·2H2O, and 0.01 g of NiCl2·6H2O. 0.03 g, 0.03 mL (10 mg / mL stock solution) of Na2SeO3·5H2O, and 0.03 mL (10 mg / mL stock solution) of Na2WO4·2H2O were added to the above test solution. Stir continuously during the addition process to keep the solution clear for later use.
[0074] Preparation of VFA-mix: Measure 90 mL of acetic acid, 30 mL of propionic acid, 10 mL of n-valeric acid, 10 mL of isobutyric acid, and 10 mL of butyric acid, mix well for later use, and adjust to neutrality with 5 M NaOH before use.
[0075] Preparation of triple-mixed liquid culture medium (BHI+MRS+modified GAM): weigh 19.25 g of BHI broth powder (Qingdao Haibo Biotechnology Co., Ltd., HB8297-5), 13.5 g of MRS broth powder (Guangdong Huankai Biotechnology Co., Ltd., 027312), and 15 g of modified GAM broth powder (Qingdao Haibo Biotechnology Co., Ltd., HB8518-3), dissolve in 1 L of distilled water, deoxygenate with N2 replacement and package, sterilize at 121°C for 30 min, and store in a cool and dry place.
[0076] Triple-mix solid culture medium: Add 5 g of agar powder to the triple-mix liquid culture medium (BHI+MRS+modified GAM).
[0077] Preparation of the second mixed culture medium (BHI+MRS): Weigh 19.25 g of BHI broth powder, 27.0 g of MRS broth powder, and 0.5 g of cysteine hydrochloride monohydrate (Longteng Biotechnology Co., Ltd.), dissolve in 1 L of distilled water, deoxygenate and package, sterilize at 121°C for 15 min, and store in a cool and dry place.
[0078] Preparation of BF839 culture medium: Weigh 6.0 g of potato extract powder (Beijing Solebow Technology Co., Ltd., FA0270), 10.0 g of polyvalent peptone (Beijing Solebow Technology Co., Ltd., P8950-250), 5.0 g of phenoxyethanol (Qingdao High-tech Industrial Park Haibo Biotechnology Co., Ltd., HB8277), 0.3 g of sodium thioglycolate (Shanghai Aladdin Biochemical Technology Co., Ltd., S105664-25G), 5.0 g of yeast extract powder (ThermoFisher Oxoid, LP0021B), 1.5 g of glucose (Chengdu Kelong Chemical Co., Ltd., 50-99-7), and 4.0 g of disodium hydrogen phosphate (Chengdu Kelong Chemical Co., Ltd., 7558-79-4), dissolve in 1 L of distilled water, deoxygenate with N2 replacement and package, sterilize at 121°C for 30 min, and store in a cool and dry place.
[0079] Preparation of artificial gastric juice: adjust the pH of artificial gastric juice (Shanghai Yuanye Biotechnology Co., Ltd., R30387, containing 10 g / L pepsin) to 3.0, and continue to pass N2 for 1 hour. Sterilize with a 0.22 μm filter in an anaerobic glove box and set aside. Store at 4°C for no more than 30 days.
[0080] Preparation of anaerobic PBS: Weigh 0.27g of potassium dihydrogen phosphate, 1.42g of disodium hydrogen phosphate, 8g of sodium chloride, and 0.2g of potassium chloride, dissolve in 1L of distilled water, heat to boil, cool to room temperature, add 0.55g of cysteine hydrochloride, stir to dissolve, adjust the pH to 6.5, install a quantitative dispenser and pass N2, heat to boiling, keep at a slight boiling state for 30min, cool and package into 400mL / bottle, sterilize at 121℃ high temperature and wet heat for 30min, store in a cool and dry place for later use.
[0081] GAM solid culture medium, TSB (Tryptone Soy Broth, Qingdao Haibo Biotechnology Co., Ltd., HB4114), and TSA (Tryptone Soy Agar, Qingdao Haibo Biotechnology Co., Ltd., HB4138) culture medium were prepared by weighing and dissolving according to the instructions, sterilizing with high temperature and wet heat at 121°C for 30 min, and storing in a cool and dry place.
[0082] Preparation of fermentation medium with bacterial powder: weigh 30g of anhydrous glucose, 15g of soy peptone, 10g of yeast powder, 5g of sodium acetate, 2g of dipotassium hydrogen phosphate, 0.1g of magnesium sulfate, 0.045g of manganese sulfate, 1mL of Tween 80, and 0.5g of monohydrated cysteine hydrochloride, and dissolve them in 1L of purified water. Deoxygenate by N2 replacement, aliquot, sterilize at 121℃ for 15min, and store in a cool, dry place.
[0083] Example 1: Isolation and Identification of Enterococcus avium Eaviu-1
[0084] The screening and separation method of Enterococcus avium Eaviu-1 is as follows:
[0085] Collect fresh fecal samples from healthy volunteers, add appropriate amount of anaerobic PBS to resuspend, shake, and make sure the sample is fully resuspended. Under N2 protection, filter twice through gauze, and dispense the filtrate into 50mL centrifuge tubes. Centrifuge at 10000rpm for 20min and discard the supernatant. Add appropriate amount of anaerobic PBS to resuspend the bacteria in the centrifuged precipitate, then add an equal volume of 50% anaerobic glycerol aqueous solution to mix thoroughly, and dispense into 2mL screw cap tubes, 0.5mL each. After dispensing, bag and vacuum-pack in a -80℃ refrigerator for storage.
[0086] During separation, take out one frozen sample tube, resuspend the thawed sample in anaerobic PBS at a volume ratio of 1:10 (tenfold dilution), vortex and shake for 5 minutes, transfer to the anaerobic glove box, take 0.5mL of bacterial suspension and shake in 4.5mL of anaerobic PBS to mix. Use the same tenfold dilution method as above to dilute the sample to 10 -6 , take appropriate bacterial solution gradient and mix with YCFA medium, then divide into 384-well plates and culture anaerobically at 37℃ for one week. Pick the bacterial solution from the growing wells for transfer. After 48 hours of culture, divide the bacterial solution into two parts. One part is detected by MALDI-TOF-MS to preliminarily classify the isolated strains. When it can be successfully classified, the corresponding other part is transferred to 96-well plates again according to the mass spectrometry results. After 48 hours of culture, one plate is amplified for 16S rDNA sequence and sent to Chengdu Branch of Beijing Qingke Biotechnology Co., Ltd. for sequencing. The other plate is temporarily stored by adding 50% glycerol mixed solution at a volume ratio of 1:1 and used after the PCR results are confirmed.
[0087] The 16S rDNA sequencing results of several isolated strains were analyzed and compared with the NCBI nt library. The results showed that the sequence similarity with a strain of Enterococcus avium was the highest (100%). Therefore, it was preliminarily identified as Enterococcus avium and named Eaviu-1 (abbreviated as Eaviu-1). Its colony morphology is white, opaque, and circular, with a convex center and a smooth and moist surface. The front photo is shown in Figure 1The strain was deposited in the China Center for Type Culture Collection (CCTCC) on March 17, 2023. The strain collection number is: CCTCC NO: M 2023350, the culture name is: Enterococcus avium Eaviu-1, the Chinese classification name is: Avian Enterococcus, and the English classification name is: Enterococcus avium. Its viability was tested by the China Center for Type Culture Collection (CCTCC) on March 24, 2023, and the result was survival.
[0088] Example 2: Whole genome analysis of Enterococcus avium Eaviu-1
[0089] Enterococcus avium Eaviu-1 was inoculated into 5 mL of three-mixed liquid medium at a 2% inoculum and cultured until the late logarithmic growth stage. The whole genome DNA of the strain was extracted and whole genome sequencing was performed using the Illumina high-throughput sequencing platform NovaSeq 6000. After assembly and annotation, the protein sequence was entered into the Virulence Factor Databases (VFDB) for virulence factor analysis. The results showed that the bacteria did not have virulence factors.
[0090] The novelty of the strain was analyzed by using the Average Nucleotide Identity (ANI). By searching in Genbank, 45 published Enterococcus avium genomes were found. By comparing with fastANI (v1.33), it was found that the two strains closest to the whole genome of Enterococcus avium Eaviu-1 were GCA_018917545.1 (ANI = 98.75%) and GCA_018373135.1 (ANI = 98.62%), so Enterococcus avium Eaviu-1 can be considered a new strain. Its 16SrDNA sequence is shown in the following sequence 1 (SEQ ID NO.1).
[0091] The whole genome was annotated by emapper-2.1.9, and it was found that Eaviu-1 contained two gene sequences of acetogenic enzymes. Among them, the amino acid sequence of the first acetogenic enzyme is shown in the following sequence 2 (SEQ ID NO.2), and the amino acid sequence of the second acetogenic enzyme is shown in the following sequence 3 (SEQ ID NO.3).
[0092] Eaviu-1 also contains a gene encoding an enzyme related to propionate production, the amino acid sequence of which is shown in the following sequence 4 (SEQ ID NO.4).
[0093] Eaviu-1 also contains a gene encoding SagA protein, the amino acid sequence of which is shown in the following sequence 5 (SEQ ID NO.5).
[0094] Eaviu-1 also contains a gene encoding a SOD-related enzyme, the amino acid sequence of which is shown in the following sequence 6 (SEQ ID NO.6).
[0095] Sequence 1
[0096]
[0097] sequence2
[0098] MKRIGILTSGGDAPGMNAAVRAVVRKAIFEGMEVYGYNYGFAGLVAGDIRRLDVADVGDKIQRGGTFLYSARYPEFATEEGQLKGIEQLKKFGIEGLVVIGGDGSYHGALALTKHGYPAVGIPGTIDNDIPGTDFTVGFDTAINTVLESVDRIRDTATSHVRTFVIEVMGRNAGDIALWSGVAGGADEIVIPEHDFDMERI AKKIQAGRDRGKKHCLIILAEGVMGGNEFAEKLAEYGDFHTRVSVLGHVVRGGSPARDRVLASKFGSYAVDLLLEGKGGLCIGIEENEVIASDIVETLENNKHKPDLSLYELNHQISF
[0099] sequence3
[0100] MKKTKIVSTLGPASNSVETISELIEAGANVFRFNFSHGDHEEQLTRMNMVREAVKKTGKDVGILLDTKGAEIRTTVQDTTDADYGRAGYIEFNVGDKTRISMDPEHKGTKEKIAVTYPGLFDDAHIGGHILFDDGLIDMEIIDKDEAN RELIMLVKNAGMLGSRKGVNAPGISINLPGITEKDADDIRFGLDNDINFIASFVRKAQDVLDIREILEEKNMTHVHIFPKIESQEGIDNIDEIIKVSDGIMIARGDMGVEIAPELVPMVQKRIIKKCNYAGKPVITATQMLESMQENP RPTRAEASDVANAVFDGTDATMLSGESANGKYPVEAVGTMARIDMEAESALSELGSFQINEFDKSNVTETIGLSVARAAKNLGVKTIVAATESGHTARMISKYRPDADILAVTFDEHTKRSLMVNWGVYPTVAEKPTTTDDMFDLAAQKAVDLGFAKEGDLILITAGVPVGERGTTNVMKVQMIGSKLLQAQGIGESTVVAHAVVAKNAEEAIKKAKDGMVLVVPTTDKDYMPAIEKASALIVEDGGLTSHAAVVGIAQDIPVVVGADSATSTVVDGELVTVDPRRGIVYRGQTTAI
[0101] sequence4
[0102] MSSIEHFSHKDINKKNRLFSNIRSVIETAFYGNNVTRIRHLTDAYALAKSSPGTITTTDLDVAYTSRLQLPTAKVLVTNDGKIVGRTAAARRIIGQEGIDADFYSELLREAVFQARSKKFYSGEVIVGLDEEFTVKSH LMVPADYSPNLYSYLLNFQIGDAKHLFYQQSDEIYTGDFFIFADPDWEHPDFPDGVVVIDPLHNCAGILGLRYFGELKKATLTLAWATAHRNGFIACHGGMKQYLLEDKKYTMAAFGLSGSGKSTITLAKPKNKGEVHV LHDDAFVISKDKGSTTALEPAYFDKTQDYPMSSEQIKYIVTAQNVGVTLDEENKKVLVTEDIRNGRGSIKSRYATPNRVDHIDEKVDGLFWIMKDDSLPPVIKIEDPSLAAVFGATLATKRSTAENVVGEVADQLVIE PFANPFRCYPLQEDYQDFKDLFQKKKTDCYILNTGDFKGRKVTPEETLGSIEKIIDGSAEEFKPFGPLKGISYLPVKKHEPDFNSHHYLIHLMTRLETRLAFVQSRKTYQGGYDRLPNEAEQLLLYLLDQLHNYKETITV
[0103] sequence 5
[0104] MKKSLLSALMVCSVTLSALAAPAAASADEFDSKIADQDAKISSLQNQ QTDAQSQISALEGEVASINDKAQGLLNEQESLRQKSQELQKQIETLDKRIEKRSEAIKEQARDTQVKQSSGTNVIDVVLNAESFTDAVSRVQAMTTIVKANNDLVEQQKADKAEVEQKQAENKKQQEQIAANQATLESQKGDLIAKQADLNVQTTTLAAEQATAESDKASLKEKQEAAIKEQQRVQEEARKAAEAQEAAKKADAEAKEKADADAKAEADRKAQEEAAASTTTTESSSSTVESSSTEQTQSSTVDSSATESSNEDNFQGGGATPTTPSESGTGNTNSNNQGSTSSTTNNQTPSTPAPTPTPTPTPTPAPSGNGSGVVAEAMKYIGTPYVWGGKTPAGFDCSGFTSYVFRQATGREIGGWTVPQESAGTRISVGEAQAGDLYFWGSPGGTYHVAIAMGGGQYIHAPQPGETVTVSSVSYYAPSFAVRM
[0105] Sequence 6
[0106] MAYTLPDLPYGYDALEPYIDVETMHLHHDKHHNTYVTNLNAAIEKYPELGEQSIEELMKNLNEVPEDIRTAVRNNGGGHANHSFFWKIMAPNAGGEPTGAIKDAIDQAFGSFEKMKEEFKTAATGRFGSGWAWLVLNNGKLEITSTANQDSPLTDGKTPIIGLDVWEHAYYLKYKNVRPDYIAAFWDVVNWDQANENLANAK
[0107] Example 3: Hemolysis test of Enterococcus avium Eaviu-1
[0108] The preserved Enterococcus avium Eaviu-1 was inoculated into 5mL of three-mixed liquid medium at a 2% inoculation rate, and cultured anaerobically at 37°C until the late logarithmic growth period to obtain an activated strain. 2mL of 2% fresh rabbit red blood cell suspension (Beijing Borsi Technology Co., Ltd.) and 2mL of 0.9% sterile saline (Shandong Qidu Pharmaceutical Co., Ltd.) were taken and resuspended to perform liquid contact method detection, with an equal volume of sterile water as a positive control (hemoglobin is released after red blood cells absorb water and burst), and an equal volume of 0.9% sterile saline as a negative control. Each group was paralleled for 3 times, and each sample was photographed after standing for 24 hours. The results showed that the negative control was not hemolytic, the positive control was hemolytic, and the Enterococcus avium Eaviu-1 bacterial suspension had no hemolytic phenomenon, which met the basic requirements for the safety of intestinal probiotics.
[0109] Example 4: Gastric juice resistance of Enterococcus avium Eaviu-1
[0110] Inoculate avian enterococci Eaviu-1 into 5 mL of three-mixed liquid medium at a 2% inoculum and culture until the late logarithmic growth period. Take 1 mL of bacterial suspension and centrifuge (8000 rpm, 5 min). Discard the supernatant and resuspend the bacteria in 1 mL of anaerobic PBS and pH 3.0 artificial gastric juice. After anaerobic incubation at 37°C for 3 hours, take 100 μL of the bacterial suspension and dilute it 10 times with anaerobic PBS. Take 10 -3 ~10 -5 50 μL of the gradient bacterial suspension was mixed with a three-mix solid medium containing 0.5% agar powder, and cultured anaerobically at 37°C until a single colony grew and then counted, with 3 parallels per group. Gastric juice resistance survival rate of the strain = (number of live bacteria in the gastric juice incubation group / number of live bacteria in the PBS incubation group) × 100%.
[0111] Experimental results: The number of viable bacteria of Enterococcus avium Eaviu-1 after incubation in anaerobic PBS for 3 hours was (3.53±0.51)×10 7 CFU / mL; after treatment with pH 3.0 gastric juice, the number of viable bacteria was (3.70±0.12)×10 7 CFU / mL, and the tolerance rate to pH 3.0 gastric juice was 104.72±3.53%. Eaviu-1 has strong tolerance to pH 3.0 gastric juice and has the basic property of being a probiotic and not being digested in the intestine.
[0112] Example 5: Antioxidant Experiment of Enterococcus avium Eaviu-1
[0113] The preserved Enterococcus avium Eaviu-1 was activated and inoculated into 5 mL BF839 medium at a 2% inoculum size. Lactobacillus rhamnosus GG (Lactobacillus rhamnosus, CICC6141, China Industrial Microbiological Culture Collection Center) was used as a positive control. All strains were anaerobically cultured in BF839 medium at 37°C for 24 h.
[0114] Sample processing: Take 0.5mL of culture solution and centrifuge at 12000rpm for 20min, discard the supernatant, and resuspend with 0.5mL of the extract (pre-cooled) in the strain total antioxidant capacity detection kit (the kit was purchased from Beijing Solebow Technology Co., Ltd., BC1315); transfer to a sterilized screw-cap tube containing beads (Sigma, USA, G4649-1KG), oscillate and break the wall once with a rapid sample preparation instrument (parameter setting: 4.5m / s, 30s), centrifuge at 12000rpm and 4℃ for 10min, take the supernatant and place it on ice for testing.
[0115] A BCA protein concentration determination kit (the kit was purchased from Beijing Solebow Technology Co., Ltd., PC0020) was used to draw a standard curve and detect BCA samples according to the instructions of the kit.
[0116] The total antioxidant capacity detection kit of strains was used to determine the antioxidant capacity of the samples according to the instructions of the kit and the standard curve. The total antioxidant capacity unit is μmol / mg prot.
[0117] The experimental results can be found in Figure 2 :Depend on Figure 2 The results showed that the total antioxidant capacity of strain Eaviu-1 reached 0.402±0.181μmol / mgprot, which was significantly higher than that of the positive control strain Lactobacillus rhamnosus GG (p<0.05), indicating that Lsali-1 has strong antioxidant capacity in vitro.
[0118] Example 6: Antibacterial ability of Enterococcus avium Eaviu-1 against pathogenic bacteria
[0119] In this example, two common pathogenic bacteria that cause diarrhea were selected for antibacterial ability testing. The source information of the pathogenic strains is as follows:
[0120] Pseudomonas aeruginosa (CMCC(B)10104) was purchased from China Food and Drug Inspection Institutes.
[0121] Clostridium difficile (CICC 22951) was purchased from China Industrial Microbiological Culture Collection Center.
[0122] Obtaining Enterococcus avium fermentation broth: After being activated, Enterococcus avium Eaviu-1 was inoculated into a three-mixed liquid culture medium (BHI+MRS+modified GAM) at an inoculum volume of 2%, and anaerobically cultured at 37° C. for 48 hours to obtain a fermentation broth.
[0123] Preparation and coating of pathogens: Pseudomonas aeruginosa was activated by TSB broth medium and diluted 50 times in TSB broth medium to reach the appropriate concentration, and 0.2 mL of the diluted bacterial solution was coated on TSA solid medium. Clostridium difficile is an anaerobic bacterium. After anaerobic activation and transfer, it was diluted 50 times in a three-mixed liquid medium, and 0.2 mL of the diluted bacterial solution was coated on sterile anaerobic GAM solid medium (added with 5% horse serum, Beijing Solebow Technology Co., Ltd., S9050).
[0124] Co-cultivation of avian enterococci and pathogenic bacteria: Place 3 sterilized Oxford cups on the coated pathogenic bacteria plate, add 0.2 mL of avian enterococci fermentation liquid into the Oxford cups, place in an anaerobic culture box (anaerobic pathogens plus anaerobic gas production bag), place the plate upright for 24 hours, and measure the size of the inhibition zone with a vernier caliper.
[0125] The results are as follows Figure 3 As shown: Avian Enterococcus has antibacterial ability against both Pseudomonas aeruginosa and Clostridium difficile, and has a stronger antibacterial ability against Clostridium difficile.
[0126] Example 7: In vitro cell inflammation inhibition test of Enterococcus avium Eaviu-1
[0127] THP-1 cell polarization:
[0128] RPMI-1640 (ThermoFisher, C11875500BT) medium containing 10% FBS and a final concentration of 100 ng / mL Phorbol 12-myristate 13-acetate (Sigma-Aldrich Company, P1585) was used to generate 1×10 5 THP-1 cells were seeded in a 96-well plate at a seeding density of 10 cells / well and placed in a 5% CO2 incubator at 37°C for 24 h to polarize them into mature macrophages.
[0129] Strain culture: Inoculate 200 μL of Enterococcus avium Eaviu-1 bacterial solution from the bacterial storage into 5 mL of mixed medium (BHI+MRS), and culture anaerobically in a 37°C electric constant temperature incubator for 24 hours. After transferring once, culture anaerobically for 8 hours. Take 1 mL of bacterial solution, centrifuge at 5000 rpm / min for 15 minutes. Dilute the strain to 5×10 with RPMI-1640 medium containing 10% FBS. 7 CFU / mL is reserved.
[0130] Effect of Enterococcus avium Eaviu-1 on the expression of TNF-α and IL-6 in THP-1 cells: After the mature THP-1 cells were cultured, the normal control group was replaced with RPMI-1640 medium containing 10% FBS; the model group, positive control group and Eaviu-1 test group were replaced with RPMI-1640 medium containing 10% FBS, a final concentration of 100ng / mL LPS (Sigma-Aldrich Company, L3024) and 20ng / mL IFN-γ (PeproTech, AF-300-02) to model inflammatory macrophages. Each group was placed in a 5% CO2 incubator and cultured at 37°C for 24h. The culture medium was aspirated, and 100 μL of RPMI-1640 culture medium containing 10% FBS was added to the normal control group and the model group, respectively; 100 μL of RPMI-1640 culture medium containing 10% FBS and dexamethasone (purchased from Sigma-Aldrich Company, D4902-25) with a final concentration of 25 μg / mL was added to the positive control group; 100 μL of the fermented Lactobacillus Eaviu-1 culture medium prepared in advance was added to the Eaviu-1 test group. After being placed in a 5% CO2 incubator and cultured at 37°C for 24h, 80μL of cell culture medium was taken from each group, centrifuged at 4°C, 5000rpm / min for 15min, and the supernatant was collected. The TNF-α content was detected using a Human TNF-α (Tumor Necrosis Factor Alpha) ELISA kit (purchased from Wuhan Elaruite Biotechnology Co., Ltd., E-EL-H0109c), and the IL-6 content was detected using a Human IL-6 (Interleukin 6) ELISA kit (purchased from Wuhan Elaruite Biotechnology Co., Ltd., E-EL-H6156).
[0131] Experimental results: Figure 4 As shown, the expression of IL-6 and TNF-α in the model group cells was significantly higher than that in the normal control group (P<0.01); the positive control dexamethasone group was able to significantly inhibit the expression of proinflammatory factors IL-6 and TNF-α in THP-1 cells (P<0.01); the avian Enterococcus Eaviu-1 group was also able to significantly reduce the expression of proinflammatory factors IL-6 and TNF-α (P<0.01), and the effect was comparable to that of Yangshen dexamethasone, indicating that the strain has a strong anti-inflammatory effect in vitro.
[0132] Example 8: Therapeutic effect of Enterococcus avium Eaviu-1 on 5-fluorouracil (5-FU)-induced diarrhea in mice
[0133] Lyophilization protective agent preparation:
[0134] Solution A: 8g sucrose, 8g trehalose, 44g purified water, sterilized at 115℃ for 30min;
[0135] Solution B: arginine hydrochloride 2g, sodium glutamate 2g, purified water 16g, sterilized at 115℃ for 30min;
[0136] Solution C: 4g of sodium vitamin C, 16g of purified water, filter and sterilize for later use.
[0137] When using, mix in a volume ratio of A:B:C=6:2:2.
[0138] Preparation of bacterial powder: The preserved avian enterococcus Eaviu-1 was inoculated into the bacterial powder preparation fermentation medium at a 10% inoculation rate, and anaerobically cultured at 37°C and 90 rpm to obtain a primary seed solution (OD 600 Then, the inoculation amount of 1.5% was transferred to the bacterial powder to prepare the fermentation medium, and the secondary seed solution (OD 600 The secondary seeds were inoculated at 1.5% with a peristaltic pump into a fermentation tank containing bacterial powder and fermentation medium, and the fermentation parameters (temperature 37°C, pH=6.0, speed 100rpm, pressure control 0.06MPa) were set to start fermentation. 600 Value ≥2.0 or OD 600 When the value increases by ≤0.1, stop fermentation and collect the bacterial cells. Divide the bacterial liquid into centrifuge buckets, centrifuge and discard the supernatant. Add lyophilization protective agent at a weight ratio of 1:1 to 1:2 to emulsify the bacterial slurry. Place the emulsified bacterial suspension on a freeze dryer cooled to -40°C and freeze-dry. After the freeze-drying process is completed, take out the bacterial cake and crush it to obtain bacterial powder. Before administering the drug to the animals, use 0.2 mL of normal saline to mix 1×10 9 CFU bacterial powder is prepared into bacterial suspension.
[0139] Experimental animals: 20 SPF-grade male Balb / c mice, weighing 18-22 g, were purchased from Beijing Weitonglihua Experimental Animal Technology Co., Ltd. and kept in an SPF-grade animal room.
[0140] Experimental design: 5-FU (5-fluorouracil, purchased from Tianjin Jinyao Pharmaceutical Co., Ltd., specification 10mL / tube, 0.25g / 10mL) solution was used to induce a chemotherapy-related diarrhea model in mice. The mice were randomly divided into 4 groups according to their initial body weight, namely normal control group, model control group, positive control loperamide group, and avian Enterococcus Eaviu-1 group, with 5 mice in each group.
[0141] The total experimental period was 9 days, recorded as D1-D9. A single 5-FU model was created on D3. Except for the normal control group, which was intraperitoneally injected with normal saline, all other groups were treated with a single 5-FU intraperitoneal injection of 350 mg / kg (body weight).
[0142] All groups were given drugs by gavage. The normal control group and the model control group were given lyophilized protective agent by gavage. The positive control group was given 20 mg / kg (body weight) of loperamide (purchased from Xi'an Janssen Pharmaceutical Co., Ltd.) by gavage for 9 consecutive days. The Eaviu-1 group was given 1×10 9 CFU avian Enterococcus. After the end of D5 administration, the observation was continued for 4 days. The specific experimental groups and administration schemes are shown in Table 1.
[0143] Table 1. Trial groups and dosing regimen
[0144]
[0145] Note: 5-FU: 5-fluorouracil; CFU: colony forming unit; d: day
[0146] Diarrhea observation and scoring: Place mice in a mouse cage lined with clean filter paper, one per cage. Hard stools and normal stools are scored as 0 points; mild, slightly wet stools or soft stools are scored as 1 point; moderate, wet stools, unformed stools and unclean perianal area are scored as 2 points; severe, loose stools and severe unclean perianal area are scored as 3 points. During the experimental period, the feces of mice were observed and scored every day. The total diarrhea score was the sum of the daily diarrhea scores.
[0147] Test results: Figure 5 As shown in the figure, compared with the model group, Eaviu-1 and loperamide administration had a significant improvement effect on 5-FU-induced diarrhea ( Figure 5 A); Enterococcus avium Eaviu-1 and loperamide could significantly reduce the total score of diarrhea (P<0.01) ( Figure 5 B).
[0148] Conclusion: Enterococcus avium Eaviu-1 can significantly improve 5-FU-induced diarrhea in mice.
[0149] It is known from common technical knowledge that the present invention can be implemented by other embodiments that do not deviate from its spirit or essential features. Therefore, the above disclosed embodiments are only illustrative in all respects and are not exclusive. All changes within the scope of the present invention or within the scope equivalent to the present invention are included in the present invention.
Claims
1. A biomaterial, wherein the biomaterial is selected from the following M1, M2, M3 and M4; M1: Enterococcus avium with a deposit number of CCTCC NO: M2023350 or a lysate thereof; M2: a progeny strain of Enterococcus avium with a deposit number of CCTCC NO: M2023350 or a lysate thereof; M3: a cloned strain of Enterococcus avium with a deposit number of CCTCC NO: M2023350 or a lysate thereof; M4: pure culture of Enterococcus avium with a deposit number of CCTCC NO: M2023350 or a lysate thereof.
2. A method for culturing avian Enterococcus, the method comprising: inoculating avian Enterococcus with a deposit number of CCTCC NO: M2023350, a progeny strain of the avian Enterococcus with a deposit number of CCTCC NO: M2023350, a cloned strain of the avian Enterococcus with a deposit number of CCTCC NO: M2023350, or a pure culture of the avian Enterococcus with a deposit number of CCTCC NO: M2023350 into a culture medium, performing proliferation culture, and obtaining proliferated avian Enterococcus.
3. A composition comprising the biomaterial according to claim 1 as an active material.
4. The composition according to claim 3, characterized in that The composition further contains auxiliary materials.
5. The composition according to claim 3, characterized in that The auxiliary material is selected from any one of the following materials: Bacterial culture medium; Lyoprotectants; Pharmaceutically acceptable carriers or excipients; Acceptable materials in health products; acceptable materials in cosmetics; Materials acceptable in food.
6. Use of the biomaterial according to claim 1 or the composition according to any one of claims 3 to 5 in the preparation of a product for use alone or in combination with other microbial agents and / or drugs to improve the health of a subject; The improving the health condition of the subject is selected from: Treat, prevent and / or relieve chemotherapy-induced diarrhea; Inhibiting the proliferation of Pseudomonas aeruginosa and / or Clostridium difficile in the body cavity of the subject; Treat, prevent and / or slow down tissue damage, disease or sub-health condition caused by Pseudomonas aeruginosa and / or Clostridium difficile; Treat, prevent and / or alleviate tissue damage, disease or sub-health condition caused by TNF-α and / or IL-6; Improve the antioxidant capacity in the intestines of subjects.
7. The use according to claim 6, characterized in that The product is selected from medicines, health products, foods and cosmetics.
8. The use according to claim 6, characterized in that The subject is selected from humans and mice.
9. The use according to claim 6, characterized in that The chemotherapy drugs are selected from fluorouracil chemotherapy drugs, taxane chemotherapy drugs, platinum chemotherapy drugs, topoisomerase I inhibitors, and tyrosine kinase inhibitors.
10. The use according to claim 9, characterized in that The chemotherapy drug is selected from one or more of doxorubicin, epirubicin, dactinomycin D, doxorubicin, daunorubicin, paclitaxel, docetaxel, albumin paclitaxel, cisplatin, carboplatin, nedaplatin, oxaliplatin, lobaplatin, cyclophosphamide, nitrogen mustard, carmustine, camptothecin, hydroxycamptothecin, topotecan, irinotecan, capecitabine, gemcitabine, methotrexate, 5-fluorouracil, pemetrexed, and cytarabine.
